Sellas' blood cancer immunotherapy cuts death risk in trial
Published 2 d ago1 sourceEvidence: Reported
CG Oncology reported that its investigational immunotherapy for bladder cancer reduced the risk of tumor recurrence by 68% in a clinical trial. The results, if confirmed, could shift treatment paradigms for certain patients. The data are from a company press release and have not been independently verified.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 19 h ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported